Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 1908-1919, 2021.
Artículo
en Inglés
| WPRIM
| ID: wpr-887633
ABSTRACT
Immunotherapy has dramatically altered the treatment of non-small cell lung cancer. Currently, the emergence of combination strategies in immunotherapy has brightened the prospects of improved clinical outcomes and manageable safety profiles in the first/second-line settings. However, sub-optimal response rates are still observed in several clinical trials. Hence, alternative combination models and candidate selection strategies need to be explored. Herein, we have critically reviewed and commented on the published data from several clinical trials, including combined immunotherapy and chemotherapy, anti-angiogenic agents, epidermal growth factor receptor/anaplastic lymphoma kinase tyrosine kinase inhibitors, radiotherapy, and other immune checkpoint inhibitors.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de la Angiogénesis
/
Inhibidores de Proteínas Quinasas
/
Inmunoterapia
/
Neoplasias Pulmonares
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Chinese Medical Journal
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS